Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06282965

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI).

The main questions this trial aims to answer are:

* Is Angiotensin (1-7) safe? * Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI?

Participants will:

* Complete 21 days of study treatment consisting of a once-daily injection. * Provide blood samples. * Undergo two magnetic resonance imaging (MRI) scans of the brain. * Complete specific tasks and questionnaires that allow researchers to evaluate the participant's brain and psychological functioning.

Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Traumatic Brain Injury Brain Diseases Brain Injuries Brain Injuries, Traumatic Central Nervous System Diseases Craniocerebral Trauma Nervous System Diseases Trauma, Nervous System Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Arizona

Tucson, Arizona, 85724, United States

Location status: Recruiting

Location contact

Clinical Research Coordinator

CONTACT

[email protected]

520-237-6845

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant or representative willing to provide informed consent.
  • Age 18 years or older at time of enrollment.
  • Traumatically induced head injury resulting from insult to head from an external force.
  • Clinical diagnosis of acute intracranial lesion based on neuroradiologist report. CT scan and report must be available.
  • Moderate or severe traumatic brain injury (TBI) defined as Glasgow Coma Scale (GCS) score on trauma presentation of 12 or less. In general: Moderate TBI will be defined as loss of consciousness between 30 minutes and 24 hours and GCS between 9 and 12. Severe TBI will be defined as loss of consciousness > 24 hours and GCS ≤ 9.
  • Enrollment within 48 hours of TBI.

Exclusion criteria

  • Time of injury cannot be determined.
  • Neurosurgery within the last 30 days.
  • History of neurodegenerative disease or disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors that would impact cognitive testing.
  • Contraindication to having an MRI.
  • Pregnant or lactating female.
  • Female of childbearing potential or sexually active male who is not willing to use an acceptable method of birth control for the treatment period and 7 days after the last dose of the study drug.
  • Participation in another clinical study involving investigational product within 30 days prior to study enrollment.
  • If in the opinion of the investigator, candidate is unsuitable for participation in the study.

Treatment and study plan

Angiotensin (1-7)

Drug

The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.

Other names: Angiotensin I/II (1-7) acetate

Sterile Saline

Drug

Sterile solution of 0.9% NaCl in water.

Other names: Sterile sodium chloride

Primary outcomes

  1. Number of participants with adverse events

    Time frame: At 21 days

    The number of participants with adverse events in each group will be compared in order to determine whether Angiotensin (1-7) is significantly associated with the occurrence of adverse events.

  2. Performance on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)

    Time frame: 90 days

    The Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment consisting of eleven tasks. It is used to assess cognitive function. Errors in each task are summed for a total score ranging from 0 to 70. Higher scores represent greater cognitive dysfunction, with a score of 0 representing the least impairment and a score of 70 representing the greatest impairment.

Secondary outcomes

  1. Cognitive functions after Angiotensin (1-7) treatment as measured by the Montreal Cognitive Assessment (MoCA)

    Time frame: 90 days

    Difference in performance for the treatment groups compared to controls on the Montreal Cognitive Assessment (MoCA). The range of possible scores is 0-30, with scores of 26 and above being considered normal.

  2. Function after Angiotensin (1-7) treatment, as measured by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)

    Time frame: 90 days

    Differences between the treatment groups and controls on the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), a 23-item inventory to assess daily functioning by asking about the participant's performance of multiple activities in the past four weeks. Scores range from 0 to 78, with 0 indicating the greatest disability.

  3. Effects of Angiotensin (1-7) on acute CNS damage biomarker phosphorylated tau (p-tau)

    Time frame: Enrollment to 21 days

    Change in phosphorylated tau (p-tau), a biomarker which can predict cognitive decline, cognitive impairment, and dementia.

  4. Effects of Angiotensin (1-7) on CNS damage biomarker phosphorylated tau (p-tau) after 90 days

    Time frame: Enrollment to 90 days

    Change in phosphorylated tau (p-tau), a biomarker which can predict cognitive decline, cognitive impairment, and dementia.

  5. Effects of Angiotensin (1-7) on brain white matter integrity

    Time frame: MRI baseline to 90 days

    Assessment of difference in white matter integrity calculated from MR images.

  6. Effects of Angiotensin (1-7) on length of hospital stay

    Time frame: Admission to discharge, average of 5 days

    Length of stay will be calculated as the difference between the admission and discharge dates.

  7. Incidence and duration of delirium as assessed by the Confusion Assessment Method (CAM)

    Time frame: Admission to discharge, average of 5 days

    The Confusion Assessment Method (CAM) is used to diagnose delirium using an algorithm based on the following features:

    • Acute onset and fluctuating course.
    • Inattention.
    • Disorganized thinking.
    • Altered level of consciousness.

  8. Change in suicidal ideation and behavior as assessed by the Patient Health Questionnaire (PHQ-9)

    Time frame: Enrollment to 21 days, enrollment to 90 days

    The Patient Health Questionnaire (PHQ-9) is a brief questionnaire used to assess the severity of symptoms of depression. The range of possible scores is 0-27, with a higher score indicating greater depression severity.

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Research Coordinator

CONTACT

[email protected]

(520) 237-6845

Sponsors and collaborators

Lead sponsor

University of Arizona

Other

Collaborators

  • United States Department of Defense

Registry information

Official study title

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

Acronym: ANGel T

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Feb 28, 2024
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.